- FDA Approves GoldenBiotech’s IND Application of Antroquinonol for Phase II Trial on Relapsed Acute Myeloid Leukemia (AML)
- 100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
- COVID-19 Scoop: Epoch-Making GoldenBiotech’s Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
Golden Biotechnology Corporation (GBC), founded by Mr. Sheng Yung, Liu in 2002, is an leading and innovative drug discovery and evidence-based healthy food supplement manufacturing company dedicated to enhancing lives by developing high quality products that prevent and treat diseases.
GBC’s main focus is on new drug R&D, IP right, pharmacology, toxicology and clinical studies. GBC also has successfully built up the screening platforms to identify bioactive compounds from traditional Chinese herbal medicine that includes more than 480 kinds of local plants, 1300 species of fungi, mushrooms and seaweeds.
Throughout 2002-2005, around 400 drug candidates were obtained from these screening platforms. Based on our own core chemical database, the ubiquinone-like structure of Antroquinonol® was actually discovered in 2006 during drug development. The pharmacology and toxicology of Antroquinonol® have been established along with the CMC (Chemistry, Manufacturing, and Controls) development and large-scale cGMP manufacturing of Antroquinonol®.